Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

o of 1:1 to receive either selumetinib (75mg, orally, twice daily) or matching placebo in combination with docetaxel (intravenously, 75mg / m2, on day one of every 21 day cycle).  SELECT-1 will be the largest prospective study ever conducted in this patient population, a genetic sub-type of lung cancer associated with poor prognosis and limited treatment options. 

AstraZeneca's decision to progress selumetinib to Phase 3 in NSCLC followed the results from a randomized Phase 2 study evaluating the combination of selumetinib with docetaxel against docetaxel alone in KRAS-mutation positive NSCLC. This study demonstrated a high and durable response rate of 37.2% vs 0% (p<0.0001), translating into a statistically significant improvement in PFS of 5.3 vs 2.1 months (HR 0.58, p<0.014).

Antoine Yver, Vice President and Head of Oncology in AstraZeneca's Global Medicines Development unit said: "To our knowledge, SELECT-1 will be the first Phase 3 study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone in advanced or metastatic non-small cell lung cancer.  This is an area of pressing clinical need, and our decision to progress selumetinib was based on Phase 2 results, which showed promising clinical activity in this group of patients." 

AstraZeneca is also investigating the potential for selumetinib in several types of MEK-dependent cancers.  A pivotal Phase 2 study assessing the efficacy and tolerability of selumetinib combined with radioactive iodine (RAI) as adjuvant therapy in patients with differentiated thyroid cancer with high risk of recurrence started in August 2013, and a further Phase 2 study assessing the clinical efficacy and tolerability in combination with dacarbazine in patients with metastatic uveal melanoma is planned to start in late 2013.

About selumetinib
Selumetinib is an oral, potent, selective ME
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 Huntington Memorial Hospital is the first ... aortic valve replacement (TAVR), a minimally invasive replacement of ... way to replace an aortic valve without a chest ... The procedure is performed by a dedicated ... Alex) Durairaj , MD, interventional cardiologist and Robbin ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... According to a new market ... (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), ... - Global Forecasts to 2019", published by MarketsandMarkets, the ... Million growing at a CAGR of 11.50% by 2019. ... figures spread through 195 pages and in-depth TOC on ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... OMER ), a biopharmaceutical company committed to ... and disorders of the central nervous system, today announced ... December 31, 2010. Financial ResultsTotal ... 2010 were $9.5 million, compared to $5.7 million for ...
... 15, 2011 ARMSRx Pharmacy Benefit Consulting, the nation,s ... provided successful recommendations for their clients. ... their premier clients, 84 Lumber.  It was recommended and ... were made available by making some simple changes.  The ...
Cached Medicine Technology:Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 2Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 3Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 4Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 5Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 6ARMSRx and 84 Lumber Hammer Down Rx Costs...Again 2
(Date:3/28/2015)... Virginia (PRWEB) March 28, 2015 ARDX will ... 28th from 12pm -3pm at the Chesapeake Conference Center in ... by sponsoring an empowering event for women in the Hampton ... Weaving the Stories of Women’s Lives. Women grow stronger ... from each other. This year the WWC™ theme is ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 LTW Cyber ... agreed to collaborate for the purpose of addressing the ... venture will pursue its own opportunities to grow while ... part of LTW Cyber. , Ventures in LTW Cyber ... and complemented by offerings identifying vulnerabilities and analyzing open ...
(Date:3/27/2015)... Red Deer, Alberta (PRWEB) March 27, 2015 ... had, until then, prevented her from working, Monica K. arrived ... day in the mending department quiet, defensive and scared. The ... Employment Placement & Support Services (EPSS) to offer jobs ... it does take patience and a willingness to begin with ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 First Choice ... today. The new facility is located 12665 W Lake Houston ... a resident of Summerwood, I look forward to delivering the ... Dr. Sowell, Facility Medical Director of First Choice Emergency Room ... Emergency Room made a donation to Summer Creek High School ...
(Date:3/27/2015)... March 27, 2015 Healthpointe is proud ... Katz, M.D., is now treating knee and hip joint ... Anaheim , Long Beach, and La Mirada. Dr. Stanley ... knee and hip joint disorders as well as chronic ... passionate in returning his patients back to their normal ...
Breaking Medicine News(10 mins):Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... , ... Inc., developers of the AcceleDent System , which is an ... Director of Sales in the UK. Ms. Davies has spent ... industry, most recently for nine years as a senior manager with ...
... , ... 16 MassMutual,s Retirement Services Division has announced plans to introduce ... platform will include a full suite of enrollment, transition and investment ... the option to choose from a menu of creative options to ...
... Imaging is at the heart of diagnostic procedures in ... Cardiovascular Imaging which accumulates the expertise of European cardiovascular ... unique in that it is written with a patient ... condition to the patient, with the aid of imaging. ...
... ... wellness programs have a positive impact on employee presenteeism and bottom line benefits. ... Minneapolis, MN (PRWEB) ... percent of employers have improved employee participation in health and wellness programs by implementing ...
... Switzerland, Dec. 16 Tyco International Ltd. (NYSE: ... for election to the Tyco Board of Directors at the ... Daniels, 55, is Senior Vice President of the Global Technology ... he has worldwide responsibility for IBM,s Global Services business operations ...
... Fla., Dec. 16 Dale Buchanan, owner of Supreme Ultimate Fitness ... his students in the new year. The difference with this contest is that ... They will be losing weight to raise money for the Tri County ... student of mine loses between January 4 and February 28, 2010 I will ...
Cached Medicine News:Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2
Oxygen Conservation Device. Bypass 6203: Turn knob....
... Micro Shafts For Insertion Through A 1.0mm ... ... For A More Comfortable Approach., ,Recessed Jaws ... Supplied For Protection Of Jaws During Sterilization., ...
A Combination Fixation Ring With A Platform Provides A Physiologically Spherical And Low-Reflective Smooth Surface To Place A Reflected Flap For Undersurface Laser Ablation Of The Posterior Flap....
... Cut Foldable Lenses Through A Small Incision ... Designed To Cut And Remove Even High ... With One Instrument., ,Ideal For Cutting ... Damaged, The Wrong Diopter Power, Or Need ...
Medicine Products: